Лекции

Софосбувир-содержащие схемы противовирусной терапии хронического гепатита С, актуальные в Российской Федерации в 2018 г

После регистрации в Российской Федерации софосбувира (Совальди ®) особую актуальность приобрели схемы противовирусной терапии хронического гепатита С (ХГС) на основе этого препарата. В статье обсуждаются данные об эффективности четырех вариантов лечения, зарегистриро ванных в Российской Федерации: софосбувир + рибавирин, софосбувир + пегилированный интерферон (Пег-ИФН)-α /рибавирин, софосбувир + симепревир, софос бувир + даклатасвир. Для обоснования использования в обычной клинической практике софосбувир-содержащих схем лечения в определенных группах больных авторы использовали частоту стойкого вирусологического ответа (СВО) 90%, причем в обязательном порядке учи ≥ тывалась расчетная условная стоимость конкретной схемы лечения в ценах 2018 г.

Полный текст статьи не опубликован.

Используемые источники

  1. Herbst DA, Reddy KR. S):1–112. ofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22(4):527-36.
  2. Lawitz E, Mangia A, Wyles D, et al. S):1–112. ofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87.
  3. Jacobson IM, Gordon S):1–112. C, Kowdley KV, et al; POS):1–112. ITRON S):1–112. tudy; FUS):1–112. ION S):1–112. tudy. S):1–112. ofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867-77.
  4. Zeuzem S):1–112. , Dusheiko GM, S):1–112. alupere R, et al; VALENCE Investigators. S):1–112. ofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370(21):1993-2001.
  5. S):1–112. ulkowski MS):1–112. , Naggie S):1–112. , Lalezari J, et al.; PHOTON-1 Investigators. S):1–112. ofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312(4):353-61.
  6. Molina JM, Orkin C, Iser DM, et al; PHOTON-2 study team. S):1–112. ofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098-106.
  7. Lawitz E, Mangia A, Wyles D, et al. S):1–112. ofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87.
  8. Foster GR, Pianko S):1–112. , Brown A, et al; BOS):1–112. ON S):1–112. tudy Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149(6):1462-70.
  9. Kalal C, S):1–112. hukla A, Mohanka R, et al. S):1–112. ofosbuvir, Peg Interferon & Ribavirin for retreatment of HCV genotype 1b following S):1–112. ofosbuvir and Ledipasvir failure. Hepatology 2017, doi: 10.1002/hep.29667 [Epub ahead of print].
  10. Raboisson P, de Kock H, Rosenquist A, et al. S):1–112. tructure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS):1–112. 3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 2008;18(17):4853-8.
  11. Lawitz E, Matusow G, DeJesus E, et al. S):1–112. imeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: Aphase 3 study (OPTIMIS):1–112. T-2). Hepatology 2016;64(2):360-9.
  12. Hezode C, Chevaliez S):1–112. , S):1–112. coazec G, et al. Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS):1–112. 5A inhibitor–containing regimen. AAS):1–112. LD 2015, Poster S):1–112. ession 2, Abstract 1123.
  13. Hezode C, Chevaliez S):1–112. , S):1–112. coazec G, et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed adaclatasvir-containing regimen. Hepatology 2016;63(6):1809-16.
  14. Herbst DA, Reddy KR. NS):1–112. 5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22(10):1337-46.
  15. S):1–112. ulkowski MS):1–112. , Gardiner DF, Rodriguez-Torres M, et al; AI444040 S):1–112. tudy Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211-21.
  16. Nelson DR, Cooper JN, Lalezari JP, et al; ALLY-3 S):1–112. tudy Team. All-oral 12week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61(4):1127-35.
  17. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016;63(5):1430-41.
  18. Wyles DL, Ruane PJ, S):1–112. ulkowski MS):1–112. , et al; ALLY-2 Investigators. Daclatasvir plus S):1–112. ofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373(8):714-25.
  19. Poordad F, S):1–112. chiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63(5):1493-505.
  20. Zarkua J, Zakalashvili M, Gish RG, Metreveli D. Identification of Recombinant S):1–112. trains in HCV Genotype 1 and 3: Is it needed? Liver Int 2018, doi: 10.1111/liv.13729.
  21. Zakalashvili M, Zarkua J, Weizenegger M, et al. Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia. Liver Int 2018;38(3):451-7.
  22. Paolucci S):1–112. , Premoli M, Ludovisi S):1–112. , et al. HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy. Antivir Ther 2017;22(4):365-8.
  23. Kalinina O, Norder H, Mukomolov S):1–112. , Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in S):1–112. t. Petersburg. J Virol 2002;76(8): 4034-43.
  24. De Keukeleire S):1–112. , Descheemaeker P, Reynders M. Potential risk of misclassification HCV 2k/1b strains as HCV 2a/2c using VERS):1–112. ANT HCV Genotype 2.0 assay. Diagn Microbiol Infect Dis 2015;82(3):201-2.
  25. Kurbanov F, Tanaka Y, Chub E, et al. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. J Infect Dis 2008;198(10):1448-56.
  26. Todt D, S):1–112. chlevogt B, Deterding K, et al. S):1–112. uccessful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. J Antimicrob Chemother 2017;72(5):1541-3.
  27. Mukomolov S):1–112. , Trifonova G, Levakova I, et al. Hepatitis C in the Russian Federation: challenges and future directions. Hepat Med 2016;8:5

Версия на английском языке